Cipla, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by strong domestic demand, and said the U.S. freezing aid for some drug programs would not hurt its results.

Cipla reported a 48.73% increase in consolidated net profit for Q3 2024. The growth was attributed to improved performance across various markets, despite challenges in the US. The company's revenue rose to Rs 7,

For the first nine months of the financial year, Cipla's EBITDA margin 26.9%, which is higher than the management guidance of 24.5% to 25.5% for the full year.

Cipla , one of India's largest drugmaker by sales, reported a bigger-than-expected third-quarter profit on Tuesday, helped by strong demand, especially in the key North American market.